147 related articles for article (PubMed ID: 38687198)
21. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
Ten Hacken E; Burger JA
Biochim Biophys Acta; 2016 Mar; 1863(3):401-413. PubMed ID: 26193078
[TBL] [Abstract][Full Text] [Related]
22. AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.
Cosimo E; Tarafdar A; Moles MW; Holroyd AK; Malik N; Catherwood MA; Hay J; Dunn KM; Macdonald AM; Guichard SM; O'Rourke D; Leach MT; Sansom OJ; Cosulich SC; McCaig AM; Michie AM
Clin Cancer Res; 2019 Mar; 25(5):1574-1587. PubMed ID: 30559170
[TBL] [Abstract][Full Text] [Related]
23. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
Reiff SD; Mantel R; Smith LL; Greene JT; Muhowski EM; Fabian CA; Goettl VM; Tran M; Harrington BK; Rogers KA; Awan FT; Maddocks K; Andritsos L; Lehman AM; Sampath D; Lapalombella R; Eathiraj S; Abbadessa G; Schwartz B; Johnson AJ; Byrd JC; Woyach JA
Cancer Discov; 2018 Oct; 8(10):1300-1315. PubMed ID: 30093506
[TBL] [Abstract][Full Text] [Related]
24. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
Blunt MD; Koehrer S; Dobson RC; Larrayoz M; Wilmore S; Hayman A; Parnell J; Smith LD; Davies A; Johnson PWM; Conley PB; Pandey A; Strefford JC; Stevenson FK; Packham G; Forconi F; Coffey GP; Burger JA; Steele AJ
Clin Cancer Res; 2017 May; 23(9):2313-2324. PubMed ID: 27697994
[No Abstract] [Full Text] [Related]
25. Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.
Zhang XT; Hu XB; Wang HL; Kan WJ; Xu L; Wang ZJ; Xiang YQ; Wu WB; Feng B; Li JN; Gao AH; Dong TC; Xia CM; Zhou YB; Li J
Acta Pharmacol Sin; 2021 May; 42(5):814-823. PubMed ID: 32855532
[TBL] [Abstract][Full Text] [Related]
26. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
[TBL] [Abstract][Full Text] [Related]
27. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
28. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
Reiff SD; Muhowski EM; Guinn D; Lehman A; Fabian CA; Cheney C; Mantel R; Smith L; Johnson AJ; Young WB; Johnson AR; Liu L; Byrd JC; Woyach JA
Blood; 2018 Sep; 132(10):1039-1049. PubMed ID: 30018078
[TBL] [Abstract][Full Text] [Related]
29. Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
Xia M; Luo TY; Shi Y; Wang G; Tsui H; Harari D; Spaner DE
J Immunol; 2020 Nov; 205(10):2629-2639. PubMed ID: 33067379
[TBL] [Abstract][Full Text] [Related]
30. Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK.
Krysov S; Steele AJ; Coelho V; Linley A; Sanchez Hidalgo M; Carter M; Potter KN; Kennedy B; Duncombe AS; Ashton-Key M; Forconi F; Stevenson FK; Packham G
Blood; 2014 Nov; 124(20):3101-9. PubMed ID: 25170122
[TBL] [Abstract][Full Text] [Related]
31. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ
Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722
[TBL] [Abstract][Full Text] [Related]
32. Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
Hanna BS; Yazdanparast H; Demerdash Y; Roessner PM; Schulz R; Lichter P; Stilgenbauer S; Seiffert M
Haematologica; 2021 Apr; 106(4):968-977. PubMed ID: 32139435
[TBL] [Abstract][Full Text] [Related]
33. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
ten Hacken E; Burger JA
Pharmacol Ther; 2014 Dec; 144(3):338-48. PubMed ID: 25050922
[TBL] [Abstract][Full Text] [Related]
34. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.
Lorenzo-Herrero S; Sordo-Bahamonde C; Bretones G; Payer ÁR; González-Rodríguez AP; González-García E; Pérez-Escuredo J; Villa-Álvarez M; Núñez LE; Morís F; Gonzalez S; López-Soto A
Front Immunol; 2019; 10():2455. PubMed ID: 31681329
[TBL] [Abstract][Full Text] [Related]
35. FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia.
Seda V; Vojackova E; Ondrisova L; Kostalova L; Sharma S; Loja T; Mladonicka Pavlasova G; Zicha D; Kudlickova Peskova M; Krivanek J; Liskova K; Kren L; Benes V; Musilova Litzmanova K; Borsky M; Oppelt J; Verner J; Pospisilova S; Brychtova Y; Panovska A; Tan Z; Zhang S; Doubek M; Amruz Cerna K; Mayer J; Mraz M
Blood; 2021 Sep; 138(9):758-772. PubMed ID: 33786575
[TBL] [Abstract][Full Text] [Related]
36. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
37. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
38. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
[TBL] [Abstract][Full Text] [Related]
39. Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.
Amin NA; Balasubramanian S; Saiya-Cork K; Shedden K; Hu N; Malek SN
Clin Cancer Res; 2017 Feb; 23(4):1049-1059. PubMed ID: 27535981
[No Abstract] [Full Text] [Related]
40. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
Kim E; Ten Hacken E; Sivina M; Clarke A; Thompson PA; Jain N; Ferrajoli A; Estrov Z; Keating MJ; Wierda WG; Bhalla KN; Burger JA
Leukemia; 2020 Jun; 34(6):1588-1598. PubMed ID: 31862959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
